

Ref. No: 107010622  
From: Commercial  
Date: 01/06/22  
Subject: Usage of somatropins

## REQUEST

a. How many patients have you treated in the last 12 months with the following drugs?

- Genotropin
- Humatrope
- Norditropin
- Nutropin
- Omnitrope
- Saizen
- Zomacton
- Any other Somatropin (please specify)

b. Please provide the number of patients under the age 16 that were treated in the last 12 months with each of the following drugs:

- Genotropin
- Humatrope
- Norditropin
- Nutropin
- Omnitrope
- Saizen
- Zomacton

## RESPONSE

**Pharmacy Response:**

Issues between 1<sup>st</sup> June 2021 and 1<sup>st</sup> June 2022

We have no patients recorded under the age of 16 treated during this period.

	PATIENTS
SOMATROPIN 'GENOTROPIN GOQUICK'	<5
SOMATROPIN 'GENOTROPIN MINIQUEL'	<5
SOMATROPIN 'NORDITROPIN SIMPLE Xx'	<5
SOMATROPIN 'NUTROPIN AQ'	<5

Please note <5 : We are unable to provide precise figures when those figures refer to individuals in volumes of 5 or less due to the risk that individuals will be re-identified, as we are required to protect their identity under the General Data Protection Regulations & Data Protection Act 2018. In such circumstances sections 40(2) and (3) of the Freedom of Information Act apply. In this case, our view is that disclosure would breach the first data protection principle. This states that personal data should be processed "lawfully, fairly and in a transparent manner". It is the lawful aspect of this principle which, in our view, would be breached by disclosure. In such circumstances section 40 confers an absolute exemption on disclosure.